IDEXX Laboratories, Inc. IDXX NDXSPXR3KPHARMA

Q: What is the current share price of IDEXX Laboratories, Inc. (IDXX)?

As of 2026-09-07 16:24 PDT, IDEXX Laboratories, Inc. (IDXX) trades at $535.38 on NasdaqGS. Its 52-week range is $526.44 to $766.68.

Q: What is the market capitalisation of IDXX?

IDEXX Laboratories, Inc. (IDXX) has a market capitalisation of $42.23B on NasdaqGS.

Q: What is the P/E ratio of IDXX?

IDXX trades at a trailing price-to-earnings (P/E) ratio of 37.65. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 29.87.

Q: What is the return on equity (ROE) of IDXX?

IDXX has a return on equity (ROE) of 74.21%. Its return on capital employed (ROCE) is 61.76%.

Q: Is IDXX a good stock to buy?

This page provides a data-driven analysis of IDEXX Laboratories, Inc. (IDXX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Diagnostics & Research · United States

https://www.idexx.com

Company Profile ↓

$535.38

-19.36% 1Y

Mkt Cap$42.23B

P/E37.65

P/B29.87

52W High$766.68

52W Low$526.44

Book Value$19.64

EPS (TTM)$14.22

Company Overview

IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 74.2%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 61.8%.

Consistent Profit Growth

Net profit has compounded at 14.8% per year over the last five years.

Healthy Margins

Maintains a net profit margin of 25.0%.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Dec 2025 Revenue of $4.30B (+10.4% YoY); net profit $1.06B.
Trailing 12 Months Year-on-year growth — revenue +9.7%, earnings +17.6%.
5-Year Trend Long-term compounding — revenue CAGR 9.4%, profit CAGR 14.8%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	9.39%
1 Year:	9.70%

Compounded Profit Growth

5 Years:	14.82%
1 Year:	17.60%

Stock Price Performance

1 Year:	-19.36%
6 Months:	-12.00%
3 Months:	-4.76%
1 Month:	-9.26%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish

52-Week Range 4% of range

$526.44 $766.68

Trend Signals

Price vs 50-DMABelow
Price vs 200-DMABelow
RSI (14)41.35 · Neutral

Price Performance

1M-9.26%

3M-4.76%

6M-12.00%

1Y-19.36%

Valuation vs Sector

P/E of 37.65 is above the sector median of 25.17 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Strong return on equity of 74.2%.
Healthy ROCE of 61.8%.
Excellent profit margin of 25.0%.
Profit CAGR of 14.8% over 5 years.
Generates positive free cash flow.

CONS

Trading 30.2% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

37.65

Industry PE

25.17

Forward P/E

32.41

PEG Ratio

3.61

Book Value

$19.64

Price to Book

29.87

P/S

10.16

EV/EBITDA

29.05

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

9.39%

Profit 5Y

14.82%

Revenue (YoY)

9.70%

Earnings (YoY)

17.60%

Profitability & Returns

ROCE

61.76%

ROE

74.21%

ROA

27.08%

Profit Margin

25.03%

Op Margin

34.98%

Gross Margin

62.45%

EPS (Latest Qtr)

$4.27

EPS (TTM)

$14.22

Balance Sheet & Liquidity

Debt/Equity

0.68

Quick Ratio

0.73

Current Ratio

1.17

Debt

$1.10B

Total Assets

$3.44B

Current Assets

Working Capital

Ownership

Promoter Holding

0.22%

Chg in Prom Hold

0.00%

FII / Inst Holding

96.85%

Chg in FII Hold

0.02%

Financial Snapshot

Enterprise Value

$42.23B

Total Revenue (TTM)

$4.55B

EBITDA

$1.62B

Free Cash Flow

$909.37M

Operating Cash Flow

$1.37B

Shares Outstanding

78.88M

Gross Margin

62.45%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	IDXX IDEXX Laboratories, Inc. NDXSPXR3KPHARMA	535.38	37.65	$42.23B	0.00%	61.76%	74.21%	9.39%	14.82%
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,149.36	38.57	$1.02T	0.58%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	275.23	31.97	$663.28B	2.09%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	256.46	72.45	$453.19B	2.84%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	150.33	120.26	$371.29B	2.65%	-	34.70%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	397.14	25.54	$356.47B	2.33%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	159.99	24.20	$304.10B	3.03%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	162.70	24.36	$252.33B	1.98%	15.97%	21.96%	9.82%	45.96%
9	AMGN Amgen Inc. NDXSPXR3KPHARMA	437.23	27.14	$235.98B	2.49%	13.95%	91.47%	5.51%	5.55%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	-	-	-	-	-	-	-	462.02M	508.94M	491.98M	506.12M	537.66M	580.75M	545.45M	549.39M	576.06M	620.10M	605.30M	605.45M	626.34M	637.59M	721.79M	777.71M	826.14M	810.42M	836.55M	860.55M	841.66M	900.20M	943.63M	915.53M	964.10M	1.00B	975.54M	998.43M	1.11B	1.11B	1.09B	1.14B	1.22B
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	375.05M	414.73M	421.88M	432.46M	418.08M	-
Gross Profit	232.76M	224.27M	217.69M	227.54M	260.54M	246.73M	240.63M	258.19M	292.71M	274.00M	272.47M	303.10M	332.44M	305.64M	300.36M	331.60M	357.85M	344.95M	331.15M	359.59M	379.34M	422.61M	470.78M	489.31M	472.92M	498.75M	514.03M	506.63M	542.97M	572.85M	547.98M	593.07M	619.16M	596.04M	623.38M	694.73M	683.35M	658.11M	722.74M	779.09M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	306.85M	321.69M	328.51M	342.51M	360.15M	-
Operating Income	88.30M	71.89M	66.91M	73.79M	104.16M	88.46M	83.83M	92.24M	122.56M	100.41M	97.81M	113.04M	145.59M	117.35M	115.35M	133.14M	164.28M	139.80M	115.63M	144.32M	193.25M	171.86M	247.62M	259.25M	225.96M	248.34M	179.07M	244.83M	280.40M	296.14M	275.28M	298.96M	263.80M	303.89M	316.53M	373.05M	354.85M	315.61M	362.59M	425.57M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	351.81M	409.44M	392.05M	354.91M	400.87M	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7.67M	11.32M	10.65M	9.21M	7.74M	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	310.08M	362.35M	344.77M	306.98M	355.44M	-
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	67.41M	68.36M	70.16M	58.79M	77.00M	-
Net Income	56.91M	44.22M	44.35M	46.02M	67.20M	56.45M	52.37M	69.02M	85.36M	70.51M	38.26M	89.45M	108.69M	93.25M	85.64M	102.68M	125.71M	108.84M	90.50M	111.83M	148.94M	146.22M	204.26M	202.58M	175.24M	193.97M	131.98M	180.94M	214.05M	224.24M	212.23M	235.58M	203.30M	232.84M	242.68M	293.99M	274.61M	248.19M	278.45M	338.41M
Diluted EPS	0.60	0.48	0.48	0.51	0.74	0.62	0.58	0.77	0.95	0.79	0.43	1.01	1.23	1.05	0.98	1.17	1.43	1.24	1.04	1.29	1.72	1.69	2.35	2.34	2.03	2.27	1.56	2.15	2.55	2.67	2.53	2.81	2.44	2.80	2.96	3.63	3.40	3.08	3.47	4.27
R&D Expense	24.32M	24.86M	-	24.62M	25.41M	25.67M	-	25.79M	27.00M	27.59M	-	29.02M	29.51M	29.19M	-	31.51M	32.26M	34.26M	-	33.31M	31.64M	37.52M	37.58M	37.70M	40.43M	40.17M	123.22M	48.01M	44.67M	46.51M	47.97M	52.63M	55.45M	53.98M	59.06M	61.90M	63.41M	-	65.79M	65.43M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	1.02B	1.03B	1.10B	1.22B	1.29B	1.38B	1.49B	1.60B	1.78B	1.97B	2.21B	2.41B	2.71B	-	3.37B	3.66B	3.90B	4.30B
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.36B	1.47B	1.52B	1.64B
Gross Profit	529.77M	526.28M	578.62M	646.51M	699.15M	756.12M	816.12M	890.27M	975.44M	1.10B	1.24B	1.37B	1.57B	-	2.00B	2.19B	2.38B	2.66B
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.11B	1.09B	1.25B	1.30B
Operating Income	172.46M	175.97M	203.88M	236.22M	262.56M	266.76M	260.25M	299.91M	350.24M	413.03M	491.33M	552.85M	694.52M	-	898.76M	1.10B	1.13B	1.36B
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.01B	1.22B	1.27B	1.51B
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	39.86M	41.58M	31.20M	38.85M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	859.97M	1.06B	1.11B	1.32B
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	180.88M	216.13M	221.96M	264.73M
Net Income	116.17M	122.22M	141.28M	161.79M	178.27M	187.80M	181.91M	192.08M	222.04M	263.14M	377.03M	427.72M	581.78M	-	679.09M	845.04M	887.87M	1.06B
Diluted EPS	1.87	2.01	2.37	2.78	3.17	1.74	1.79	2.05	2.44	2.94	4.26	4.89	6.71	-	8.03	10.06	10.67	13.08
R&D Expense	70.67M	65.12M	68.60M	76.04M	82.01M	88.00M	98.26M	99.68M	101.12M	109.18M	117.86M	133.19M	141.25M	161.01M	254.82M	190.95M	219.79M	251.21M

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Jan 2018	Dec 2018	Jan 2019	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	808.53M	897.14M	1.03B	1.10B	1.23B	1.38B	1.47B	1.53B	1.71B	1.74B	1.54B	1.62B	1.83B	2.29B	2.44B	2.75B	3.26B	3.29B	3.35B
Total Equity	438.32M	438.19M	514.57M	574.24M	539.58M	636.22M	518.19M	117.52M	-84.12M	-108.35M	-54.11M	-	-9.51M	-	177.47M	632.09M	689.99M	608.74M	1.48B	1.60B	1.61B
Cash & Equivalents	60.36M	78.87M	106.73M	156.91M	183.90M	223.99M	279.06M	322.54M	128.99M	154.90M	187.68M	-	123.79M	-	90.33M	383.93M	144.45M	112.55M	453.93M	288.27M	180.07M
Long Term Debt	-	-	-	-	3.42M	2.50M	151.39M	350.00M	597.10M	593.70M	606.60M	-	601.80M	-	698.91M	858.49M	775.21M	694.39M	622.88M	449.79M	374.84M
Total Liabilities	-	-	293.95M	322.86M	491.22M	467.35M	712.30M	1.27B	1.56B	1.64B	1.77B	1.80B	1.55B	1.63B	1.65B	1.66B	1.75B	2.14B	1.78B	1.70B	1.75B
Current Liabilities	-	-	256.31M	285.11M	436.88M	406.33M	478.35M	820.91M	856.76M	934.57M	1.00B	-	770.44M	784.22M	725.34M	582.76M	763.58M	1.24B	951.55M	1.07B	1.15B

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	143.31M	174.95M	178.83M	217.91M	222.41M	246.00M	235.85M	-	-	373.28M	400.08M	459.16M	648.06M	755.55M	542.98M	906.51M	929.00M	1.18B
Investing Cash Flow	-91.59M	-53.62M	-43.19M	-94.21M	-58.13M	-86.06M	-80.41M	-	-	-138.69M	138.60M	-205.53M	-109.38M	-292.97M	-195.35M	-125.25M	-207.06M	-136.24M
Financing Cash Flow	-30.79M	-95.30M	-86.77M	-97.66M	-125.34M	-102.45M	-103.44M	-	-	-208.02M	-597.80M	-286.41M	-248.42M	-697.41M	-370.94M	-442.00M	-878.07M	-1.16B
Capital Expenditure	-89.97M	-50.66M	-38.91M	-49.68M	-57.62M	-77.61M	-60.52M	-82.92M	-64.79M	-74.38M	-115.75M	-154.97M	-106.96M	-119.55M	-148.84M	-133.63M	-120.92M	-124.68M
Free Cash Flow	53.34M	124.29M	139.93M	168.24M	164.79M	168.38M	175.32M	-	-	298.89M	284.33M	304.19M	541.11M	636.00M	394.15M	772.88M	808.08M	1.06B
Share Buybacks	132.34M	83.10M	143.09M	255.50M	132.27M	367.76M	618.16M	401.98M	304.09M	282.56M	369.32M	301.66M	182.81M	746.78M	819.71M	71.92M	837.03M	1.22B

Ratios (Annual)

Figures in %.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	51.7%	51.0%	52.4%	53.0%	54.1%	54.9%	54.9%	55.6%	54.9%	55.7%	56.1%	56.7%	58.0%	-	59.5%	59.8%	61.0%	61.8%
Operating Margin %	16.8%	17.1%	18.5%	19.4%	20.3%	19.4%	17.5%	18.7%	19.7%	21.0%	22.2%	23.0%	25.7%	-	26.7%	30.0%	29.0%	31.6%
Net Margin %	11.3%	11.8%	12.8%	13.3%	13.8%	13.6%	12.2%	12.0%	12.5%	13.4%	17.0%	17.8%	21.5%	-	20.2%	23.1%	22.8%	24.6%
ROE %	26.5%	23.8%	24.6%	30.0%	28.0%	36.2%	154.8%	-228.3%	-204.9%	-486.3%	-3,963.3%	241.0%	92.0%	-	111.6%	56.9%	55.7%	66.0%
ROCE %	-	31.9%	33.3%	39.8%	37.7%	35.5%	46.2%	48.5%	58.8%	58.3%	64.1%	49.9%	40.6%	-	59.5%	47.5%	50.7%	61.8%

Shareholding Pattern

Insiders

0.22%

Institutions

96.85%

Public Float

97.06%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	10.37%	8.17M	$4.53B
2	Vanguard Capital Management LLC	6.54%	5.15M	$2.86B
3	Vanguard Portfolio Management LLC	4.95%	3.90M	$2.16B
4	State Street Corporation	4.76%	3.75M	$2.08B
5	Invesco Ltd.	4.58%	3.61M	$2.00B
6	Geode Capital Management, LLC	3.25%	2.56M	$1.42B
7	BAMCO Inc.	2.51%	1.98M	$1.10B
8	Morgan Stanley	1.72%	1.36M	$752.62M
9	Bank Of New York Mellon Corporation	1.51%	1.19M	$662.29M
10	Arrowstreet Capital, Limited Partnership	1.35%	1.07M	$592.22M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for IDXX

Google News Mon, 07 Sep 2026

Down 16% in the Last 12 Months, Can IDEXX Stock Bounce Back in 2027? - TIKR.com

<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE53YWxOZWNwVFllMklWX0laREtGMUtVbUUxU05qNGNzZi1RMHFVcTNvdUlUMUpRLTRWWmFwTnJZN1Y3eEZkV0hLcFkwdmZ0UFlSTWh1eTIwQ3lSZzZDaDE3R09MZnNoWjNWcXpCMHdUVVNSaVA5TVBzcFRB?oc=5" target="_blank">Dow…

Google News Fri, 04 Sep 2026

IDXX: Idexx Laboratories Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits

<a href="https://news.google.com/rss/articles/CBMiSkFVX3lxTE83YVozc21EVURMRW5KVGxzclIxTXk1d3pOWnk1ZVZ0LXpMSU05ajRRNTVrVy1YNVl0Wkpsd1ZMQlhnWnVUMnlRQkdB?oc=5" target="_blank">IDXX: Idexx Laboratories Inc Latest Stock Price, Analysis, News and…

Google News Fri, 21 Aug 2026

Is it a Prudent Move to Retain IDEXX Stock in Your Portfolio Now? - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxNZUdyV1BKd3EtTVVKWjl4OGdhcUNILVBJdEZZZ0l0T19CU0xmeDdJQkVXMy1yMFhPY000TUdiOHVpNWhsVVlTV1h0UlZYOW1jX3RDZFRWanlnYVJvMExqd0VwZzFTQkVaam91T0FZQzVDRUJvTGp0U3piNUtRVUotTnFXMlo2WmdsMndYeX…

Google News Sat, 15 Aug 2026

IDXX Stock Price and Chart — NASDAQ:IDXX - TradingView

<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTE82Um5QV2dqSUxlY0V0cE5BZGZ6YTVvZjlsSGVvSXNTZTI2ZEFkTjFwWTJNNmtHeDgxN0lFRzBDejg1V0NmSmlobTBXWDY0NUNIMjFtY0tyVVdpaXFM?oc=5" target="_blank">IDXX Stock Price and Chart — NASDAQ:IDXX</a…

Google News Sat, 05 Sep 2026

IDXX 260918 560.00P (IDXX260918P560000) Stock Options Chain | Quotes & News - Moomoo

<a href="https://news.google.com/rss/articles/CBMigANBVV95cUxNcDNtYk5kbUcwRFFmTUtFNlRicnRuZjBpQzRuSlhNRDFoeEl0RVdJOXR0RzBUSFdoUXAxY0w3ZmJabFRFRFRRMUV3RlN6V2daNjNja1BraHR3aVJIMzZGWW14UnFFX1lhUVRlMkdnQ0Q5Y1dqTjFTWW9HR0lWMnpIeVBLLVNSdzVuaVliZH…

Google News ue, 14 Jul 2026

Why IDEXX Laboratories (IDXX) Stock Is Down Today - quiverquant.com

<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxQdmJoS19wZjJmTXl6UURNQlc4RWl3OVdXSXdteWtoV1haRW5tUkxJbzRXVkU2Wm9JdEtKSUpxc2J0SDJJaTF3NDNYeExITE1NM0RINlotOHZqMEFUMVNNMXZ4czg0RzRJaDRzekpuQmRrT3VPbzlhaHppa0tQWS16SEkxUzZiV2pQTEZITj…

IDXX — Frequently Asked Questions

What is the current share price of IDEXX Laboratories, Inc. (IDXX)?

As of 2026-09-07 16:24 PDT, IDEXX Laboratories, Inc. (IDXX) trades at $535.38 on NasdaqGS. Its 52-week range is $526.44 to $766.68.

What is the market capitalisation of IDXX?

IDEXX Laboratories, Inc. (IDXX) has a market capitalisation of $42.23B on NasdaqGS.

What is the P/E ratio of IDXX?

IDXX trades at a trailing price-to-earnings (P/E) ratio of 37.65. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 29.87.

What is the return on equity (ROE) of IDXX?

IDXX has a return on equity (ROE) of 74.21%. Its return on capital employed (ROCE) is 61.76%.

Is IDXX a good stock to buy?

This page provides a data-driven analysis of IDEXX Laboratories, Inc. (IDXX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

IDEXX Laboratories, Inc. IDXX NDXSPXR3KPHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Down 16% in the Last 12 Months, Can IDEXX Stock Bounce Back in 2027? - TIKR.com

IDXX: Idexx Laboratories Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits

Is it a Prudent Move to Retain IDEXX Stock in Your Portfolio Now? - Yahoo Finance

IDXX Stock Price and Chart — NASDAQ:IDXX - TradingView

IDXX 260918 560.00P (IDXX260918P560000) Stock Options Chain | Quotes & News - Moomoo

Why IDEXX Laboratories (IDXX) Stock Is Down Today - quiverquant.com

IDXX — Frequently Asked Questions

What is the current share price of IDEXX Laboratories, Inc. (IDXX)?

What is the market capitalisation of IDXX?

What is the P/E ratio of IDXX?

What is the return on equity (ROE) of IDXX?

Is IDXX a good stock to buy?

Explore More